Advances in the use of imaging techniques in the screening and evaluation of psoriasis co-morbidities

Psoriasis is a prevalent chronic inflammatory disease, with a global incidence rate ranging from 1 % to 3%, and an estimated prevalence of 0.47% in our country. Associated comorbidities include psoriatic arthritis, metabolic syndrome, non-alcoholic fatty liver disease, uveitis, and chronic kidney disease, among others. The utilization of biologics in patients diagnosed with various forms of psoriasis has resulted in individualized variations in drug efficacy. Psoriasis co-morbidities have been demonstrated to exert a detrimental effect on the quality of life of patients suffering from psoriasis patients, in addition to determining the treatment measures for said patients. The efficacy of drugs following the administration of biologics is subject to variation according to the specific co-morbidities associated with psoriasis, highlighting the importance of early screening for such co-morbidities in optimizing the treatment of psoriasis. The advent of advanced imaging technologies in recent years has given rise to a plethora of novel imaging modalities, including intravenous ultrasound (IVUS), musculoskeletal ultrasound (MSUS), fluorescence optical imaging (FOI), and optical coherence tomography angiography (OCTA), among others. The advent of these imaging technologies has rendered the collection and processing of information about the human body more sensitive and specific. Due to the non-invasive and simple nature of most imaging examinations, this technology has become a key component of screening and evaluation. The advent of imaging technology has rendered it a potent instrument in the screening and evaluation of psoriasis co-morbidities. The utilization of imaging technology for the assessment of joint involvement, cardiovascular complications, ocular manifestations, hepatic involvement, and other organ systems has been shown to enhance the precision of early psoriasis co-morbidities diagnoses. Moreover, it provides a substantial foundation for the assessment of disease activity and prognosis. Consequently, in clinical diagnosis and treatment, it is imperative to prioritize the implementation of pertinent imaging modalities for the screening and evaluation of psoriasis co-morbidities at an early stage, thereby facilitating more effective assistance in the diagnosis and treatment of psoriasis patients. Among the relevant cutting-edge studies, there are more studies on psoriatic arthritis, cardiovascular disease and psoriasis ocular damage, and this paper summarizes these hot aspects.